Septerna (NASDAQ:SEPN) SVP Sells $126,087.39 in Stock

Septerna, Inc. (NASDAQ:SEPN) SVP Daniel Long sold 3,333 shares of the firm’s stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $37.83, for a total transaction of $126,087.39. Following the completion of the transaction, the senior vice president directly owned 96,412 shares in the company, valued at $3,647,265.96. This represents a 3.34% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Septerna Stock Down 1.9%

NASDAQ:SEPN traded down $0.70 during mid-day trading on Thursday, reaching $36.80. The company’s stock had a trading volume of 241,541 shares, compared to its average volume of 459,468. The firm has a market capitalization of $1.72 billion, a PE ratio of -68.15 and a beta of 2.30. The stock has a fifty day moving average of $37.46 and a 200-day moving average of $31.15. Septerna, Inc. has a 1 year low of $13.67 and a 1 year high of $51.10.

Septerna (NASDAQ:SEPN) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.14. The business had revenue of $26.75 million during the quarter, compared to analyst estimates of $19.22 million. Septerna had a negative net margin of 24.51% and a negative return on equity of 9.57%. On average, analysts expect that Septerna, Inc. will post -1.41 earnings per share for the current year.

Institutional Investors Weigh In On Septerna

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. TRV GP V LLC purchased a new stake in Septerna during the second quarter worth $208,160,143. TRV GP VI LLC purchased a new position in shares of Septerna in the 2nd quarter valued at about $141,048,460. BlackRock Inc. acquired a new position in Septerna in the 2nd quarter worth about $64,706,000. Jupiter Topco LLC purchased a new position in Septerna during the second quarter worth approximately $43,723,000. Finally, Goldman Sachs Group Inc. grew its stake in Septerna by 86.6% in the 4th quarter. Goldman Sachs Group Inc. now owns 2,715,129 shares of the company’s stock valued at $75,698,000 after acquiring an additional 1,260,409 shares during the period.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on SEPN shares. JPMorgan Chase & Co. raised their price objective on Septerna from $38.00 to $48.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 19th. JonesTrading increased their price target on shares of Septerna from $43.00 to $62.00 and gave the stock a “buy” rating in a report on Thursday, August 13th. HC Wainwright raised their price target on shares of Septerna from $40.00 to $60.00 and gave the stock a “buy” rating in a research report on Wednesday, August 12th. Truist Financial upped their price objective on shares of Septerna from $35.00 to $43.00 and gave the company a “buy” rating in a report on Wednesday, July 1st. Finally, Stifel Nicolaus set a $49.00 price objective on shares of Septerna in a research note on Tuesday, August 11th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $52.44.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.